Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, cells were transfected with miR-141 to investigate its effect on hepatocyte steatosis and viability as well as SIRT1 expression and activity along with AMPK phosphorylation.
|
31256424 |
2020 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data show that SCD1 is involved in nucleotide (ATP and NAD<sup>+</sup> ) metabolism and suggest that the SCD1-dependent regulation of muscle steatosis and insulin sensitivity are mediated by cooperation between AMPK- and SIRT1-regulated pathways.
|
31241768 |
2020 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, TSF improved lipid accumulation and hepatic steatosis by inducing the AMPK/SIRT1 pathway-mediated autophagy.
|
31105592 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Resveratrol, a sirtuin 1 (SIRT1) agonist, prevents ER stress and improves ER stress-induced hepatic steatosis and cell death.
|
31183612 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that RSV restored leptin sensitivity in a cellular model of hepatic steatosis in a SIRT1-independent manner.
|
31842467 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides hepatoprotective and metabolic beneficial effects, current study showed that elafibranor inhibited the progression of HFD-induced CKD through activation of renal PPAR<i>α</i>, PPAR<i>δ</i>, SIRT1, autophagy, reduction of oxidative stress, and apoptosis in mice with steatohepatitis.
|
31321239 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Metabolic derangements in hepatocytes controlled by SIRT1 play a role in the development of fatty liver in inbred animals.
|
31390551 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results revealed that the SIRT1/AMPK pathway is involved in the functions of the three flavonones, and the most effective flavonone against hepatic steatosis might be PCBG, followed by MPG and PCB.
|
30154382 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several in vitro and in vivo studies have shown the known protective effects of SIRT1 activators, such as resveratrol and SRT1720, on diabetes- or obesity-induced fatty liver and insulin resistance.
|
29402742 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In comparison with placebo, GC significantly increased Sirt1 and decreased hs-CRP, TNF-α, IL-6, ALT, and the degree of fatty liver (<i>P</i> < 0.05).
|
30263038 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigallocatechin-3-Gallate-Rich Green Tea Extract Ameliorates Fatty Liver and Weight Gain in Mice Fed a High Fat Diet by Activating the Sirtuin 1 and AMP Activating Protein Kinase Pathway.
|
29595075 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activating AMPK<i>α</i> negatively regulates Egr1 to inhibit inflammatory cytokines in high glucose. miR-34a inhibition increases phosphorylated AMPK<i>α</i> through mediating SIRT1 to suppress the development of fatty liver.
|
29681936 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo studies showed that hepatitis C virus core protein 1b-induced hepatic steatosis was attenuated in liver-specific Sirt1 KO mice by downregulation of PPARγ2 expression.
|
28898508 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that SIRT1 activation attenuated HFD‑induced liver steatosis and inflammation by inhibiting CD36 expression and the NF‑κB signaling pathway.
|
29845302 |
2018 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Molecular hydrogen protects against ischemia-reperfusion injury in a mouse fatty liver model via regulating HO-1 and Sirt1 expression.
|
30232347 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.
|
30214535 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
SIRT1 plays beneficial roles in regulating hepatic lipid metabolism, controlling hepatic oxidative stress and mediating hepatic inflammation through deacetylating some transcriptional regulators against the progression of fatty liver diseases.
|
28808418 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
|
28449683 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The SIRT1/heat shock factor 1/HSP pathway is essential for exenatide-alleviated, lipid-induced ER stress and hepatic steatosis, which provides evidence for a molecular mechanism to support exenatide and incretin mimetics as promising therapeutics for obesity-induced hepatic steatosis.(Hepatology 2017;66:809-824).
|
28439947 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Massive studies have suggested that liver steatosis is closely associated with the inhibition of silent information regulator 1 (SIRT1) and the augment of lipin1 β/α ratio mediated by ethanol.
|
28467182 |
2017 |
Steatohepatitis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adenovirus-mediated liver-specific expression of SIRT1 or a phosphor-defective S164A-SIRT1 mutant promoted fatty acid oxidation and ameliorated liver steatosis and glucose intolerance in diet-induced obese mice, but these beneficial effects were not observed in mice expressing a phosphor-mimic S164D-SIRT1 mutant.
|
28533219 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The interaction of SIRT1/Mitofusin2 is critical for maintaining mitochondrial integrity and functioning, which is disrupted upon excess lipid infiltration during the progression of steatohepatitis.
|
28247434 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Retinoic acid ameliorates high-fat diet-induced liver steatosis through sirt1.
|
28667519 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mice administered 0.02% scopolin for 8 weeks exhibited improved phenotypes of HFD-induced hepatic steatosis along with increased hepatic SIRT1 activity and protein expression.
|
28533555 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, our data support a role of Suv39h2 in promoting steatosis in mice likely through contributing to SIRT1 trans-reperssion.
|
28232186 |
2017 |